Catalent (CTLT) Azione Prezzo
Catalent Prezzo
Negli ultimi 15 anni Catalent ha aumentato il fatturato del 7,9% all'anno, raggiungendo 4,38 miliardi USD. L'utile per azione è cresciuto del 46,7% all'anno negli ultimi 8 anni. Per Catalent, il margine netto del -23,8% risulta in calo rispetto al 5,6% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Catalent è 64,77 USD, circa il 2,0% sopra il prezzo attuale di mercato. Su 14 analisti, 0 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Catalent Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Catalent Azione e analisi azionaria
Domande frequenti sull'azione Catalent
Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.
Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.
Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.
Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.
Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.
Gli analisti fissano attualmente un prezzo obiettivo medio di 64,77 USD per l’azione Catalent (mediana: 64,77 USD), pari a +2,0 % rispetto all’ultimo prezzo. Il consenso si basa su 14 giudizi di analisti.
14 analisti valutano attualmente l’azione Catalent: 0 raccomandano l’acquisto, 11 la tenuta e 3 la vendita. Per il 2026 gli analisti si aspettano per Catalent ricavi pari a 5,00 miliardi USD e un utile per azione di 1,75 USD.
Convertita al tasso di cambio attuale, l’azione Catalent quota 57,51 EUR (63,48 USD).
L’azione Catalent (CTLT) è quotata su 4 borse, tra cui: NYSE (CTLT), SIX (Zürich) (0C8.SW), Frankfurt (0C8.F), München (0C8.MU).
Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.
Il attesa fatturato di Catalent ammonta a 5,00 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Catalent ammonta a 318,65 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Catalent è attualmente 36,26. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Catalent.
Il rapporto prezzo/fatturato (P/S) di Catalent è attualmente 2,31. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Catalent.
Il Quality Score AlleAktien per Catalent è 2/10.
L'ISIN di Catalent è US1488061029. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Catalent è A112H2. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Catalent è CTLT. Con questo simbolo di borsa vengono negoziate le azioni Catalent in borsa.
Azione Catalent
Gruppo di pari di Catalent
Catalent Ticker
Catalent FIGI
Altre metriche e analisi di Catalent in Deep Dive.
La nostra analisi azionaria dell'azione Catalent include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Catalent. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: